Hyundai Bioscience-development Hyundai Bioscience, U.S. NIH to co-develop broad-spectrum antiviral drug SEOUL, Aug. 13 (Yonhap) -- Hyundai Bioscience Co. said Sunday it will develop a broad-spectrum antiviral drug with the U.S. National Institutes of Health (NIH), a federal agency for conducting and supporting medical research. Hyundai Bioscience USA, a wholly owned subsidiary of Hyundai Bioscience Co., signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) under the NIH.

https://n.news.naver.com/mnews/article/001/0014128941?sid=104

#naver